Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
AMTE Power 2.1p £0.8m (AMTE.L)
A developer and manufacturer of lithium-ion and sodium-ion battery cells for specialist markets, announces that it has conditionally placed new ordinary shares at a price of 1.7 pence per Placing Share to raise approximately £2.1m before expenses. The Issue Price represents a discount of approximately 81.62% to the closing middle market price of 9.25 pence per Ordinary Share on 7 September 2023. The net proceeds of the Placing will be used to provide further time for the Company and the potential new equity investor to complete the proposed initial equity investment of £2.5m. This placing is expected to provide the Company with working capital till early November 2023.
Atlantic Lithium 24.88p £152.3m (ALL.L)
The African-focused lithium exploration and development company targeting to deliver Ghana's first lithium mine, announces that it has agreed non-binding Heads of Terms with the Minerals Income Investment Fund of Ghana (MIIF) to invest a total of US$32.9m (£26.3m) in the Company and its Ghanaian subsidiaries. MIIF's proposed investment will support the development of the Company's flagship Ewoyaa Lithium Project (Ewoyaa) and the broader Cape Coast Lithium Portfolio in Ghana towards production. MIIF will acquire a 6% interest in the Company’s Ghana portfolio including the Ewoyaa project and the interest will take the form of funding of development, exploration and studies expenditure.
Dekel Agri-Vision 3.15p £17.6m (DKL.L)
The West African agriculture company focused on building a portfolio of sustainable and diversified projects, provides an August production update for its Ayenouan palm oil project in Côte d'Ivoire (Palm Oil Operation). August 2023 resulted in an increases in Crude Palm Oil (CPO) and Palm Kernel Oil (PKO) production of 38.3% and 103.3% compared to August 2022. CPO sales prices increased slightly to EUR822 per tonne in August 2023 compared to EUR814 per tonne achieved last month. Local CPO prices are still trading slightly below international CPO prices which traded around EUR850 per tonne in August 2023 due to higher than normal local stock supplies
Harland & Wolff Group 13.8p £23.8m (HARL.L)
The company focused on strategic infrastructure projects and physical asset lifecycle management, announces its unaudited interim results for the six-month period ended 30 June 2023 (H1 23). Revenues of £25.53m; a 65% increase (H1 22: £15.41m). EBITDA loss £15.92m (H1 22: loss of £12.71m) owing to investment in headcount in preparation for delivery of the Fleet Solid Support contract, and net debt of £88.53m (H1 22: £19.74m) reflecting the upsized Riverstone Credit Facility from $35m in March 2022 to $100m. Directors believe that trading remains on track to achieve FY23 Group revenues of £100m. Post period, the Company announced a notice to proceed for the mid-life upgrade and dry docking of a large vessel, expected to be in the region of £60-£70m in revenues and reiterates its revenue guidance for FY24 of £200m.
IQ-AI 4.2p £7.7m (IQAI.L)
Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd announces the results of a study that validates IB Neuro's processing of reduced-dose gadolinium-based contrast agent (GBCA) perfusion studies on 1.5T scanners. The multi-center study, led by Dr. Mark Shiroishi validated the use of a low-dose protocol for acquiring MRI perfusion data. In the 2019 study, it was shown that 3T MRI data collected with 50% less GBCA could provide perfusion maps comparable to the higher dose standard when processed using IB Neuro. Dynamic susceptibility contrast (DSC) MRI is the most common approach used to measure brain tumor perfusion. IB Neuro automatically processes DSC data using its unique contrast leakage (of GBCA) correction technology. The platform generates quantitative output that can be directly compared across timepoints. This study validates IB Neuro’s platform proven to provide accurate perfusion maps under low-dose conditions at both 1.5T and 3T MR scanners.
Jangada Mines 2.4p £6.2m (JAN.L)
A natural resources company with interests in Brazil, announces its unaudited interim results for the period ended six months to 30 June 2023. Pitombeiras, located in the state of Ceará, Brazil, has a Total Mineral Resource Estimate of 8.26Mt with 62% classified at the higher confidence Measured & Indicated Mineral Resources category. A technical report published in April 2022 demonstrated the project's robust economics including 100.3% post-tax IRR and US$96.5m post-tax NPV (8% discount rate). The Company held a 0.58% interest in ValOre's share capital, relating to the disposal of our previously owned PGM project held by Pedra Branca Brasil Mineração Ltda. Jangada has received a total of CAD$3m cash from ValOre and six tranches of common shares from the disposal. The Board continue to evaluate multiple value accretive commodity projects going forward.
Polarean Imaging 11.5p £24.8m (POLX.L)
A commercial-stage medical device leader in advanced magnetic resonance imaging (MRI) of the lungs, announces that it has partnered with VIDA Diagnostics (VIDA), a clinical imaging intelligence company providing medical imaging software solutions. The companies are partnering to further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use. These new products and services will be utilised to expand access to xenon 129 MRI as a lung imaging service and to investigate new indications and biomarkers in broader populations with unmet medical needs. VIDA has empowered more than 1,000 clinical and research sites globally with its imaging management platform, a cloud-native AI-enabled solution that drives standardisation and efficiencies in clinical trial imaging operations.
Power Metal Resources 0.83p £17.2m (POW.L)
The metals exploration and development company, announces the discovery of a significant helium anomaly at its 100% owned Perch River Uranium Project (Perch River) within the Athabasca Basin, Saskatchewan, Canada. The strong helium response could be indicative of significant buried uranium mineralisation or leakage of helium from a buried helium reservoir at depth. As a response to the discovery of this significant helium target, the crews currently active on the Company's uranium portfolio have been repositioned in order to complete a high-resolution soil sampling grid over this target area. The Company plans to engage a helium gas specialist to determine optimal next steps to further develop this target.
SIMEC Atlantis Energy 1.125p £8.1m (SAE.L)
The company focusing in tidal energy announces that it has successfully secured 4 Contracts for Difference (CfD) in the latest allocation round, for the world leading MeyGen site. These CfD contracts guarantees £198 (£/MWh), for 15 years from 31st March 2028 commissioning date, will allow SAE to deliver a total of c.22MW of clean, home-sourced, predictable power at its MeyGen site in Scotland. SAE has been making good progress on the delivery of the 28MW secured in the AR4 round (July 2022) and by delivering these projects in parallel, SAE will be delivering a 50MW tidal stream array, in addition to the 6MW already operational at the MeyGen site equivalent to over 65,000 homes per annum being powered by the tide.
88 Energy 0.38p £84.4m (88E.L)
An oil and gas exploration and production company with a North American focus and interests in onshore Alaska announces its half year financial report. For the period ended 30 June 2023 the Company recorded a loss of $11.6m (30 June 2022: $67.3m loss). The loss was attributable to the impairment of the Yukon Project and leases (Regenerate Energy Alaska) of $8.8m. The Group had cash on hand of $7.3m (31 December 2022: $14.1m ) and no debt. Net assets totalled A$139.6m (31 December 2022: $131.6m). The Group continued its principal exploration activities in Alaska, complemented by a 75% owned, non-operated working interest in onshore Texas Permian Basin production assets.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
